{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:01Z","timestamp":1790916961607,"version":"4.1.0"},"reference-count":40,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a\nmajor public health challenge. In this study, the Mtb proteasome was targeted as a promising site for\nnovel drug development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A total of 190,295 natural compounds from the ZINC database were screened using a systematic\napproach involving Lipinski\u2019s rule of five, SwissADME, pkCSM analysis, PyRx, and molecular\ndynamics simulation to identify potential drug candidates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Finally, five compounds, namely, ZINC14688701, ZINC299835179, ZINC14638395,\nZINC299839873, and ZINC14638400, were identified based on physicochemical, pharmacokinetics,\ndrug-likeness properties, and free energy of binding. Among these, ZINC14688701 showed the\nhighest free energy of binding (-9.3 kcal\/mol) with the selected target Mtb proteasome through the\namino acid residues Thr1, Arg19, Ser20, Thr21, Val31, Lys33, Gly47, Thr48, Ala49, Leu99, Ser141,\nand Ala180.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Finally, the complex \u2018Mtb proteasome-ZINC14688701\u2019 was studied using Molecular\nDynamics simulation (MD simulation) for 50 ns, in which RMSD, RMSF, Rg, H-bonds, and SASA\nshowed complex stability. Physicochemical evaluations revealed that the compounds are non-toxic\nwith favorable drug-likeness. Exploring the antibacterial natural inhibitors offers a promising strategy\nfor novel drug development against infectious diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These findings suggest a potential inhibitor of Mtb proteasome that could be used for\nTB treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113894501413995251031161833","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T09:36:53Z","timestamp":1767951413000},"page":"420-432","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of Natural Inhibitors against the Mycobacterium tuberculosis Proteasome: Computational Study"],"prefix":"10.2174","volume":"27","author":[{"given":"Fahad Saad","family":"Alhodieb","sequence":"first","affiliation":[{"name":"Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah, 51452, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.56786\/PHWR.2025.18.11suppl.5","volume":"18","author":"Lee H.","year":"2025","unstructured":"Lee H.; Kim J.; Kim J.; Park Y-J.; Review of the global burden of tuberculosis in 2023: Insights from the WHO global tuberculosis report 2024. PHWR  2025,18(Suppl. 11),S55-S69","journal-title":"PHWR"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.6026\/97320630012400","volume":"12","author":"Rehman A.","year":"2016","unstructured":"Rehman A.; Akhtar S.; Siddiqui M.H.; Identification of potential leads against 4-hydroxytetrahydrodipicolinate synthase from Mycobacterium tuberculosis. Bioinformation  2016,12(11),400-407","journal-title":"Bioinformation"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2174\/1568026619666190219105722","volume":"19","author":"Saxena A.K.","year":"2019","unstructured":"Saxena A.K.; Singh A.; Mycobacterial tuberculosis enzyme targets and their inhibitors. Curr Top Med Chem  2019,19(5),337-355","journal-title":"Curr Top Med Chem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1111\/febs.14029","volume":"284","author":"Bibo-Verdugo B.","year":"2017","unstructured":"Bibo-Verdugo B.; Jiang Z.; Caffrey C.R.; O\u2019Donoghue A.J.; Targeting proteasomes in infectious organisms to combat disease. FEBS J  2017,284(10),1503-1517","journal-title":"FEBS J"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1126\/science.1091176","volume":"302","author":"Darwin K.H.","year":"2003","unstructured":"Darwin K.H.; Ehrt S.; Gutierrez-Ramos J.C.; Weich N.; Nathan C.F.; The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science  2003,302(5652),1963-1966","journal-title":"Science"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/nm1683","volume":"13","author":"Gandotra S.","year":"2007","unstructured":"Gandotra S.; Schnappinger D.; Monteleone M.; Hillen W.; Ehrt S.; In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice. Nat Med  2007,13(12),1515-1520","journal-title":"Nat Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/j.1365-2958.2005.05036.x","volume":"59","author":"Hu G.","year":"2006","unstructured":"Hu G.; Lin G.; Wang M.; Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate. Mol Microbiol  2006,59(5),1417-1428","journal-title":"Mol Microbiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/386463a0","volume":"386","author":"Groll M.","year":"1997","unstructured":"Groll M.; Ditzel L.; L\u00f6we J.; Structure of 20S proteasome from yeast at 2.4\u00c5 resolution. Nature  1997,386(6624),463-471","journal-title":"Nature"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"9246","DOI":"10.1021\/acs.jmedchem.9b01187","volume":"62","author":"Zhan W.","year":"2019","unstructured":"Zhan W.; Hsu H.C.; Morgan T.; Selective phenylimidazole-based inhibitors of the Mycobacterium tuberculosis proteasome. J Med Chem  2019,62(20),9246-9253","journal-title":"J Med Chem"},{"key":"ref=10","first-page":"1","author":"Tyagi R.","year":"2020","unstructured":"Tyagi R.; Srivastava M.; Jain P.; Pandey R.P.; Asthana S.; Kumar D.; Development of potential proteasome inhibitors against Mycobacterium tuberculosis. J Biomol Struct Dyn  2020,1-15","journal-title":"J Biomol Struct Dyn"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.3390\/ijms20184331","volume":"20","author":"Pinzi L.","year":"2019","unstructured":"Pinzi L.; Rastelli G.; Molecular docking: Shifting paradigms in drug discovery. Int J Mol Sci  2019,20(18),4331","journal-title":"Int J Mol Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1021\/ci400100c","volume":"53","author":"Langdon S.R.","year":"2013","unstructured":"Langdon S.R.; Westwood I.M.; van Montfort R.L.M.; Brown N.; Blagg J.; Scaffold-focused virtual screening: Prospective application to the discovery of TTK inhibitors. J Chem Inf Model  2013,53(5),1100-1112","journal-title":"J Chem Inf Model"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2174\/157340641608201026103030","volume":"16","author":"Ahmad S.S.","year":"2020","unstructured":"Ahmad S.S.; Kamal M.A.; Current views on medicinal chemistry versus green chemistry for management of broad-spectrum health issues. Med Chem  2020,16(8),1005-1006","journal-title":"Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"103811","DOI":"10.1016\/j.compbiomed.2020.103811","volume":"122","author":"Kwofie S.K.","year":"2020","unstructured":"Kwofie S.K.; Adobor C.; Quansah E.; Molecular docking and dynamics simulations studies of OmpATb identifies four potential novel natural product-derived anti-Mycobacterium tuberculosis compounds. Comput Biol Med  2020,122,103811","journal-title":"Comput Biol Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1021\/acs.jcim.0c00171","volume":"60","author":"Zhao W.","year":"2020","unstructured":"Zhao W.; Xiong M.; Yuan X.; Li M.; Sun H.; Xu Y.; In silico screening-based discovery of novel inhibitors of Human cyclic GMP\u2013AMP synthase: A cross-validation study of molecular docking and experimental testing. J Chem Inf Model  2020,60(6),3265-3276","journal-title":"J Chem Inf Model"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1021\/acsmedchemlett.0c00011","volume":"11","author":"Newton A.S.","year":"2020","unstructured":"Newton A.S.; Faver J.C.; Micevic G.; Structure-guided identification of DNMT3B inhibitors. ACS Med Chem Lett  2020,11(5),971-976","journal-title":"ACS Med Chem Lett"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2174\/138920022009191004112826","volume":"20","author":"Ahmad S.S.","year":"2019","unstructured":"Ahmad S.S.; Kamal M.A.; Concept of drug metabolism in drug discovery pipeline. Curr Drug Metab  2019,20(9),697-700","journal-title":"Curr Drug Metab"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1021\/acs.biochem.6b01107","volume":"56","author":"Hsu H.C.","year":"2017","unstructured":"Hsu H.C.; Singh P.K.; Fan H.; Structural basis for the species-selective binding of N,C-capped dipeptides to the Mycobacterium tuberculosis proteasome. Biochemistry  2017,56(1),324-333","journal-title":"Biochemistry"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"Lipinski C.A.","year":"2004","unstructured":"Lipinski C.A.; Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol  2004,1(4),337-341","journal-title":"Drug Discov Today Technol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/jm020017n","volume":"45","author":"Veber D.F.","year":"2002","unstructured":"Veber D.F.; Johnson S.R.; Cheng H.Y.; Smith B.R.; Ward K.W.; Kopple K.D.; Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem  2002,45(12),2615-2623","journal-title":"J Med Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","volume":"1263","author":"Dallakyan S.","year":"2015","unstructured":"Dallakyan S.; Olson A.J.; Small-molecule library screening by docking with PyRx. Methods Mol Biol  2015,1263,243-250","journal-title":"Methods Mol Biol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jmgm.2017.08.023","volume":"77","author":"Jaillet L.","year":"2017","unstructured":"Jaillet L.; Artemova S.; Redon S.I.M-U.F.F.; Extending the universal force field for interactive molecular modeling. J Mol Graph Model  2017,77,350-362","journal-title":"J Mol Graph Model"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"Morris G.M.","year":"2009","unstructured":"Morris G.M.; Huey R.; Lindstrom W.; AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem  2009,30(16),2785-2791","journal-title":"J Comput Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"W48-53","DOI":"10.1093\/nar\/gkaa235","volume":"48","author":"Sch\u00f6ning-Stierand K.","year":"2020","unstructured":"Sch\u00f6ning-Stierand K.; Diedrich K.; F\u00e4hrrolfes R.; ProteinsPlus: Interactive analysis of protein\u2013ligand binding interfaces. Nucleic Acids Res  2020,48(W1),W48-53","journal-title":"Nucleic Acids Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/bioinformatics\/btl150","volume":"22","author":"Stierand K.","year":"2006","unstructured":"Stierand K.; Maa\u00df P.C.; Rarey M.; Molecular complexes at a glance: Automated generation of two-dimensional complex diagrams. Bioinformatics  2006,22(14),1710-1716","journal-title":"Bioinformatics"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"Daina A.","year":"2017","unstructured":"Daina A.; Michielin O.; Zoete V.; SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep  2017,7(1),42717","journal-title":"Sci Rep"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.drudis.2010.11.002","volume":"16","author":"Ritchie T.J.","year":"2011","unstructured":"Ritchie T.J.; Ertl P.; Lewis R.; The graphical representation of ADME-related molecule properties for medicinal chemists. Drug Discov Today  2011,16(1-2),65-72","journal-title":"Drug Discov Today"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"6752","DOI":"10.1021\/jm901241e","volume":"52","author":"Lovering F.","year":"2009","unstructured":"Lovering F.; Bikker J.; Humblet C.; Escape from flatland: Increasing saturation as an approach to improving clinical success. J Med Chem  2009,52(21),6752-6756","journal-title":"J Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","volume":"58","author":"Pires D.E.V.","year":"2015","unstructured":"Pires D.E.V.; Blundell T.L.; Ascher D.B.; pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem  2015,58(9),4066-4072","journal-title":"J Med Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1-2","author":"Abraham M.J.","year":"2015","unstructured":"Abraham M.J.; Murtola T.; Schulz R.; GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX  2015,1-2,19-25","journal-title":"SoftwareX"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1107\/S0907444904011679","volume":"60","author":"Sch\u00fcttelkopf A.W.","year":"2004","unstructured":"Sch\u00fcttelkopf A.W.; van Aalten D.M.F.; PRODRG: A tool for high-throughput crystallography of protein\u2013ligand complexes. Acta Crystallogr D Biol Crystallogr  2004,60(8),1355-1363","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.3390\/molecules26164961","volume":"26","author":"Bouback T.A.","year":"2021","unstructured":"Bouback T.A.; Pokhrel S.; Albeshri A.; Pharmacophore-based virtual screening, quantum mechanics calculations, and molecular dynamics simulation approaches identified potential natural antiviral drug candidates against MERS-CoV S1-NTD. Molecules  2021,26(16),4961","journal-title":"Molecules"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"Madhavi Sastry G.","year":"2013","unstructured":"Madhavi Sastry G.; Adzhigirey M.; Day T.; Annabhimoju R.; Sherman W.; Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des  2013,27(3),221-234","journal-title":"J Comput Aided Mol Des"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.3390\/molecules26082326","volume":"26","author":"Almeleebia T.M.","year":"2021","unstructured":"Almeleebia T.M.; Shahrani M.A.; Alshahrani M.Y.; Identification of New Mycobacterium tuberculosis Proteasome Inhibitors Using a Knowledge-Based Computational Screening Approach. Molecules  2021,26(8),2326","journal-title":"Molecules"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/978-1-59745-177-2_19","volume":"443","author":"Morris G.M.","year":"2008","unstructured":"Morris G.M.; Lim-Wilby M.; Molecular docking. Methods Mol Biol  2008,443,365-382","journal-title":"Methods Mol Biol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2000028","DOI":"10.1002\/minf.202000028","volume":"39","author":"Ton A.T.","year":"2020","unstructured":"Ton A.T.; Gentile F.; Hsing M.; Ban F.; Cherkasov A.; Rapid Identification of Potential Inhibitors of SARS\u2010CoV\u20102 Main Protease by Deep Docking of 1.3 Billion Compounds. Mol Inform  2020,39(8),2000028","journal-title":"Mol Inform"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Lin D.; Sun X.; Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science  2020,368(6489),409-412","journal-title":"Science"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1002\/slct.201600770","volume":"1","author":"Pairas G.N.","year":"2016","unstructured":"Pairas G.N.; Tsoungas P.G.; H \u2010Bond: The Chemistry\u2010Biology H \u2010Bridge. ChemistrySelect  2016,1(15),4520-4532","journal-title":"ChemistrySelect"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"12633","DOI":"10.1039\/D5CP00380F","volume":"27","author":"Yan D.","year":"2025","unstructured":"Yan D.; Ma Y.; Chen X.; Deng S.; Wang Q.; Molecular dynamics-driven drug discovery. Phys Chem Chem Phys  2025,27(24),12633-12651","journal-title":"Phys Chem Chem Phys"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","volume":"99","author":"Hollingsworth S.A.","year":"2018","unstructured":"Hollingsworth S.A.; Dror R.O.; Molecular dynamics simulation for all. Neuron  2018,99(6),1129-1143","journal-title":"Neuron"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501413995251031161833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/249117\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501413995251031161833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:36:35Z","timestamp":1790915795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/249117\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501413995251031161833","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}